Instil Bio Pulls Plug On Lead Drug Development

Instil Bio, Inc. (NASDAQ:TIL) stock is trading lower on Tuesday. Axion Bio Inc., a wholly-owned subsidiary of Instil, decided to discontinue clinical development of AXN-2510. AXN-2510, Instil’s lead asset, is a PD-L1xVEGF bispecific antibody in development for...

The Real Reason Behind Bitcoin’s Sudden Strength

Bitcoin (CRYPTO: BTC) is holding near the $93,000 level following a weekend rally, as political developments in Venezuela lifted broader risk sentiment across markets. What Happened: Bitcoin is entering early 2026 in a stabilization phase after its Q4 drawdown,...